Does experience change the role of systematic biopsy during MRI-fusion biopsy of the prostate?

Matthias Jahnen, Thomas Amiel, Tobias Wagner, Florian Kirchhoff, Jakob W. Büchler, Charlotte Düwel, Florestan Koll, Kay Westenfelder, Thomas Horn, Kathleen Herkommer, Valentin H. Meissner, Jürgen E. Gschwend, Lukas Lunger

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Purpose: To determine the role of biopsy experience regarding a potential benefit of additional systematic biopsies and fusion failures during MRI-targeted biopsy of the prostate. Subjects/patients and methods: We retrospectively evaluated 576 men undergoing transrectal (MRI)-targeted biopsy of the prostate by seven residents in urology between November 2019 and March 2022. Benefit of systematic biopsies (detection of ISUP ≥ 2 PCa (clinically significant PCa (csPCa)) solely in systematic biopsies) and fusion failure (detection of csPCa during systematic biopsies in the area of a reported MRI-lesion and no detection of csPCa in targeted biopsy) were compared by growing biopsy experience levels. Multivariable regression analyses were calculated to investigate the association with benefit of systematic biopsies and fusion failure. Results: The overall PCa detection rate was 72% (413/576). A benefit of systematic biopsies was observed in 11% (63/576); of those, fusion failure was seen in 76% (48/63). Benefit of systematic biopsies and fusion failure were more common among residents with very low experience compared to highly experienced residents (18% versus 4%, p = 0.026; 13% versus 3%, p = 0.015, respectively). Increasing biopsy experience was associated with less benefit from systematic biopsies (OR: 0.98, 95% CI 0.97–0.99) and less fusion failure (OR: 0.98, 95% CI 0.97–0.99). Conclusions: The benefit of systematic biopsies following targeted biopsy decreases with growing biopsy experience. The higher risk of fusion failure among inexperienced residents necessitates systematic biopsies to ensure the detection of csPCa. Further prospective trials are warranted before a targeted only approach can be recommended in routine clinical practice.

Original languageEnglish
Pages (from-to)2699-2705
Number of pages7
JournalWorld Journal of Urology
Volume41
Issue number10
DOIs
StatePublished - Oct 2023
Externally publishedYes

Keywords

  • MRI-targeted prostate biopsy
  • Prostate cancer
  • Residents in urology
  • Systematic biopsy

Fingerprint

Dive into the research topics of 'Does experience change the role of systematic biopsy during MRI-fusion biopsy of the prostate?'. Together they form a unique fingerprint.

Cite this